We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Monday
May 18
17:00 - 18:10
A1 Plenary
Lung cancer 3
Arturo Navarro-Martin, Spain;
Peter van Rossum, The Netherlands
Proffered Papers
Clinical
17:00 - 18:00
A Phase III Randomized Trial of Adaptive Hypofractionated Radiotherapy for Stage III Non-Small Cell Lung Cancer Based on Dynamic Contrast-Enhanced MRI
Hui Liu, China
-3155
17:00 - 18:00
Updated clinical outcomes and cytokine analysis from the Re-induction trial (NCT03406468): hypofractionated RT plus immunotherapy in metastatic NSCLC
Valentina Bartolomeo, Italy
-3506
17:00 - 18:00
Acute Toxicities of Moderately Hypofractionated Chemoradiation with Consolidation Immunotherapy in Unresectable Stage III NSCLC: Phase II Study
Shalini Vinod, Australia
-1691
17:00 - 18:00
Survival outcomes of thoracic radiotherapy (TRT) for extensive-stage small cell lung cancer (ES-SCLC) in the immunotherapy era: A Meta-Analysis
Ajay Kondeti,
-591
17:00 - 18:00
Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) for Centrally Located Lung Tumors: Interim Results from the Multicenter STRICT Lung Trial
Mette Pøhl, Denmark
-2294
17:00 - 18:00
Single-fraction SABR for primary NSCLC and lung oligometastases: a pooled analysis of 1691 patients
Neil Wallace, Australia
-3912
17:00 - 18:10
Identifying high-risk stage IIIA-N2 NSCLC patients who may benefit from PORT: secondary analyses from the Lung ART Trial
Antonin Levy, France
-2093